[1]
|
W.H.O. (2019) The Global TB Report 2019. World Health Organization, Geneva. https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf
|
[2]
|
Ben Amor, Y., Nemser, B., Singh, A., Sankin, A. and Schluger, N. (2008) Underreported Threat of Multidrug-Resistant Tuberculosis in Africa. Emerging Infectious Diseases, 14, 1345-1352. https://doi.org/10.3201/eid1409.061524
|
[3]
|
Gandhi, N.R., et al. (2012) Risk Factors for Mortality among MDR- and XDR-TB Patients in a High HIV Prevalence Setting. The International Journal of Tuberculosis and Lung Disease, 16, 90-97. https://doi.org/10.5588/ijtld.11.0153
|
[4]
|
Molla, K.A., Reta, M.A. and Ayene, Y.Y. (2022) Prevalence of Multidrug-Resistant Tuberculosis in East Africa: A Systematic Review and Meta-Analysis. PLOS ONE, 17, e0270272. https://doi.org/10.1371/journal.pone.0270272
|
[5]
|
Ou, Z.-J., et al. (2021) Trends in Burden of Multidrug-Resistant Tuberculosis in Countries, Regions, and Worldwide from 1990 to 2017: Results from the Global Burden of Disease Study. Infectious Diseases of Poverty, 10, 24. https://doi.org/10.1186/s40249-021-00803-w
|
[6]
|
W.H.O. (2018) Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis.
|
[7]
|
W.H.O. (2019) ShORRT (Short, All-Oral Regimens for Rifampicin-Resistant Tuberculosis). https://www.who.int/tdr/research/tb_hiv/ShORRT-Generic-protocol.pdf
|
[8]
|
Sutton, S., Magagnoli, J. and Hardin, J.W. (2016) Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy. Pharmacotherapy, 36, 385-401. https://doi.org/10.1002/phar.1728
|
[9]
|
Mohd, S.N.A., et al. (2018) A Longitudinal Analysis of Daily Pill Burden and Likelihood of Optimal Adherence to Antiretroviral Therapy among People Living with HIV Who Use Drugs. Journal of Addiction Medicine, 12, 308-314. https://doi.org/10.1097/ADM.0000000000000403
|
[10]
|
MSF (2017) Out of Step: TB Policies in 29 Countries, 3rd Ed. https://msfaccess.org/out-step-tb-policies-29-countries-3rd-ed
|
[11]
|
Mafukidze, A.T., Calnan, M. and Furin, J. (2015) Peripheral Neuropathy in Persons with Tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2, 5-11. https://doi.org/10.1016/j.jctube.2015.11.002
|
[12]
|
Ebrahimi, F., Farzaei, M.H., Bahramsoltani, R., Heydari, M., Naderinia, K. and Rahimi, R. (2019) Plant-Derived Medicines for Neuropathies: A Comprehensive Review of Clinical Evidence. Reviews in the Neurosciences, 30, 671-684. https://doi.org/10.1515/revneuro-2018-0097
|
[13]
|
Hammi, C. and Yeung, B. (2017) Neuropathy. StatPearls Publishing, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK542220/
|
[14]
|
Hughes, R.A. (2002) Peripheral Neuropathy. BMJ, 324, 466-469. https://doi.org/10.1136/bmj.324.7335.466
|
[15]
|
Serap, B. (2022) Ch. 9. Neurotoxicity, Types, Clinical Manifestations, Diagnosis and Treatment. In: Suna, S., Ed., Neurotoxicity, IntechOpen, Rijeka, 489-500.
|
[16]
|
National Research Council (US) Committee on Neurotoxicology and Models for Assessing Risk (1992) Introduction: Defining the Problem of Neurotoxicity. In: Environmental Neurotoxicology, National Academies Press (US), Washington, DC. https://www.ncbi.nlm.nih.gov/books/NBK234243/
|
[17]
|
Spencer, P.S. and Lein, P.J. (2014) Neurotoxicity. In: Wexler, P., Ed., Encyclopedia of Toxicology, 3rd Edition, Academic Press, Oxford, 489-500. https://doi.org/10.1016/B978-0-12-386454-3.00169-X
|
[18]
|
Prasad, R., Singh, A. and Gupta, N. (2019) Adverse Drug Reactions in Tuberculosis and Management. Indian Journal of Tuberculosis, 66, 520-532. https://doi.org/10.1016/j.ijtb.2019.11.005
|
[19]
|
Parra, M., Stahl, S. and Hellmann, H. (2018) Vitamin B6 and Its Role in Cell Metabolism and Physiology. Cells, 7, 84. https://doi.org/10.3390/cells7070084
|
[20]
|
Shin, S.S. and Seung, K.J. (2013) 39. Tuberculosis. In: Magill, A.J., Hill, D.R., Solomon, T. and Ryan, E.T., Eds., Hunter’s Tropical Medicine and Emerging Infectious Disease, 9th Edition, W.B. Saunders, London, 416-432. https://doi.org/10.1016/B978-1-4160-4390-4.00039-4
|
[21]
|
Spitters, C.E. (2012) 90—Multidrug-Resistant Tuberculosis. In: Jong, E.C. and Stevens, D.L., Eds., Netter’s Infectious Diseases, W.B. Saunders, Philadelphia, 544-553. https://doi.org/10.1016/B978-1-4377-0126-5.00090-2
|
[22]
|
Lynch, J.B. (2013) Multidrug-Resistant Tuberculosis. Medical Clinics of North America, 97, 553-579. https://doi.org/10.1016/j.mcna.2013.03.012
|
[23]
|
Abosamak, N. and Gupta, V. (2021) Vitamin B6 (Pyridoxine). StatPearls Publishing, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK557436/
|
[24]
|
Vrolijk, M.F., Opperhuizen, A., Jansen, E., Hageman, G.J., Bast, A. and Haenen, G. (2017) The Vitamin B6 Paradox: Supplementation with High Concentrations of Pyridoxine Leads to Decreased Vitamin B6 Function. Toxicology in Vitro, 44, 206-212. https://doi.org/10.1016/j.tiv.2017.07.009
|
[25]
|
Sharma, J.B., et al. (2017) Multi Drug Resistant Female Genital Tuberculosis: A Preliminary Report. European Journal of Obstetrics & Gynecology and Reproductive Biology, 210, 108-115. https://doi.org/10.1016/j.ejogrb.2016.12.009
|
[26]
|
Manjeet, S.J. and Manik, C. (2018) Cycloserine Induced Suicidal Tendencies and Kanamycin Induced Ototoxicity in Indian MDR-TB Patient: A Case Report. Current Drug Safety, 13, 211-213. https://doi.org/10.2174/1574886313666180605095842
|
[27]
|
Cohen, A.C. (1969) Pyridoxine in the Prevention and Treatment of Convulsions and Neurotoxicity Due to Cycloserine. Annals of the New York Academy of Sciences, 166, 346-349. https://doi.org/10.1111/j.1749-6632.1969.tb54286.x
|
[28]
|
Girgis, A.S. and Lattimer, J.K. (1962) The Chemotherapy of Genitourinary Tuberculosis with Regimens Using Cycloserine. The Journal of Urology, 87, 9-12. https://doi.org/10.1016/S0022-5347(17)64897-3
|
[29]
|
Kwon, H.M., Kim, H.K., Cho, J., Hong, Y.H. and Nam, H. (2008) Cycloserine-Induced Encephalopathy: Evidence on Brain MRI. European Journal of Neurology, 15, e60-e61. https://doi.org/10.1111/j.1468-1331.2008.02171.x
|
[30]
|
Liu, Y., et al. (2015) Clinical Outcomes of Linezolid Treatment for Extensively Drug-Resistant Tuberculosis in Beijing, China: A Hospital-Based Retrospective Study. Japanese Journal of Infectious Diseases, 68, 244-247. https://doi.org/10.7883/yoken.JJID.2014.222
|
[31]
|
Dauby, N., Muylle, I., Mouchet, F., Sergysels, R. and Payen, M.C. (2011) Meropenem/Clavulanate and Linezolid Treatment for Extensively Drug-Resistant Tuberculosis. The Pediatric Infectious Disease Journal, 30, 812-813. https://doi.org/10.1097/INF.0b013e3182154b05
|
[32]
|
Ramírez-Lapausa, M., Pascual Pareja, J.F., Carrillo Gómez, R., Martínez-Prieto, M., González-Ruano Pérez, P. and Noguerado Asensio, A. (2016) Retrospective Study of Tolerability and Efficacy of Linezolid in Patients with Multidrug-Resistant Tuberculosis (1998-2014). Enfermedades Infecciosas y Microbiología Clínica, 34, 85-90. https://doi.org/10.1016/j.eimc.2015.04.003
|
[33]
|
Schecter, G.F., Scott, C., True, L., Raftery, A., Flood, J. and Mase, S. (2010) Linezolid in the Treatment of Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases, 50, 49-55. https://doi.org/10.1086/648675
|
[34]
|
Swaminathan, A., du Cros, P., Seddon, J.A., Mirgayosieva, S., Asladdin, R. and Dusmatova, Z. (2017) Peripheral Neuropathy in a Diabetic Child Treated with Linezolid for Multidrug-Resistant Tuberculosis: A Case Report and Review of the Literature. BMC Infectious Diseases, 17, 417. https://doi.org/10.1186/s12879-017-2499-1
|
[35]
|
Anger, H.A., Dworkin, F., Sharma, S., Munsiff, S.S., Nilsen, D.M. and Ahuja, S.D. (2010) Linezolid Use for Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, New York City, 2000-06. Journal of Antimicrobial Chemotherapy, 65, 775-783. https://doi.org/10.1093/jac/dkq017
|
[36]
|
Garcia-Prats, A.J., et al. (2019) Pharmacokinetics, Optimal Dosing, and Safety of Linezolid in Children with Multidrug-Resistant Tuberculosis: Combined Data from Two Prospective Observational Studies. PLOS Medicine, 16, e1002789. https://doi.org/10.1371/journal.pmed.1002789
|
[37]
|
Youssef, S., et al. (2008) The Role of Vitamin B6 in the Prevention of Haematological Toxic Effects of Linezolid in Patients with Cancer. Journal of Antimicrobial Chemotherapy, 61, 421-424. https://doi.org/10.1093/jac/dkm506
|
[38]
|
Spellberg, B., Yoo, T. and Bayer, A.S. (2004) Reversal of Linezolid-Associated Cytopenias, but Not Peripheral Neuropathy, by Administration of Vitamin B6. Journal of Antimicrobial Chemotherapy, 54, 832-835. https://doi.org/10.1093/jac/dkh405
|
[39]
|
Leggat, P.O. (1962) Ethionamide Neuropathy. Tubercle, 43, 95-96. https://doi.org/10.1016/S0041-3879(62)80054-3
|
[40]
|
Tugwell, P. and James, S.L. (1972) Peripheral Neuropathy with Ethambutol. Postgraduate Medical Journal, 48, 667-670. https://doi.org/10.1136/pgmj.48.565.667
|
[41]
|
Long, K.S. and Vester, B. (2012) Resistance to Linezolid Caused by Modifications at Its Binding Site on the Ribosome. Antimicrobial Agents and Chemotherapy, 56, 603-612. https://doi.org/10.1128/AAC.05702-11
|
[42]
|
Rucker, J.C., Hamilton, S.R., Bardenstein, D., Isada, C.M. and Lee, M.S. (2006) Linezolid-Associated Toxic Optic Neuropathy. Neurology, 66, 595-598. https://doi.org/10.1212/01.wnl.0000201313.24970.b8
|
[43]
|
Song, T., et al. (2015) Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis. EBioMedicine, 2, 1627-1633. https://doi.org/10.1016/j.ebiom.2015.09.051
|
[44]
|
Ramanathan, M.R. and Sanders, J.M. (2017) Chapter 26. Drugs Used in TB and Leprosy. In: Ray, S.D., Ed., Side Effects of Drugs Annual, Vol. 39, Elsevier, Amsterdam, 283-293. https://doi.org/10.1016/bs.seda.2017.06.025
|
[45]
|
Hamada, H., Saito, T. and Torii, J. (1979) A Case of Optico-Neuropathy Due to the Treatment with Monoamine Oxidase Inhibitor (Safrazine) (Author’s Transl). Rinsho Shinkeigaku, 19, 379-387. (In JPN)
|
[46]
|
Sutton, J., Stroup, J. and Som, M. (2016) Linezolid-Induced Serotonin Toxicity in a Patient Not Taking Monoamine Oxidase Inhibitors or Serotonin Receptor Antagonists. Proceedings (Baylor University. Medical Center), 29, 214-215. https://doi.org/10.1080/08998280.2016.11929423
|
[47]
|
Swash, M., Roberts, A.H. and Murnaghan, D.J. (1972) Reversible Pellagra-Like Encephalopathy with Ethionamide and Cycloserine. Tubercle, 53, 132-136. https://doi.org/10.1016/0041-3879(72)90030-X
|
[48]
|
Saperstein, D.S. and Barohn, R.J. (2005) Chapter 89. Polyneuropathy Caused by Nutritional and Vitamin Deficiency. In: Dyck, P.J. and Thomas, P.K., Eds., Peripheral Neuropathy, 4th Edition, W.B. Saunders, Philadelphia, 2051-2062. https://doi.org/10.1016/B978-0-7216-9491-7.50092-2
|
[49]
|
Gupta, N., Arora, M., Sharma, R. and Arora, K.S. (2016) Peripheral and Central Nervous System Involvement in Recently Diagnosed Cases of Hypothyroidism: An Electrophysiological Study. Annals of Medical and Health Sciences Research, 6, 261-266. https://doi.org/10.4103/amhsr.amhsr_39_16
|
[50]
|
Rasool, M., et al. (2015) Determination of Potential Role of Antioxidative Status and Circulating Biochemical Markers in the Pathogenesis of Ethambutol Induced Toxic Optic Neuropathy among Diabetic and Non-Diabetic Patients. Saudi Journal of Biological Sciences, 22, 739-743. https://doi.org/10.1016/j.sjbs.2014.09.019
|
[51]
|
Cole, A., May, P.M. and Williams, D.R. (1981) Metal Binding by Pharmaceuticals. Part 1. Copper(II) and Zinc(II) Interactions Following Ethambutol Administration. Agents Actions, 11, 296-305. https://doi.org/10.1007/BF01967631
|
[52]
|
Lessell, S. (1976) Histopathology of Experimental Ethambutol Intoxication. Investigative Ophthalmology & Visual Science, 15, 765-769.
|
[53]
|
Heng, J.E., Vorwerk, C.K., Lessell, E., Zurakowski, D., Levin, L.A. and Dreyer, E.B. (1999) Ethambutol Is Toxic to Retinal Ganglion Cells via an Excitotoxic Pathway. Investigative Ophthalmology & Visual Science, 40, 190-196.
|
[54]
|
Akahane, K., Sekiguchi, M., Une, T. and Osada, Y. (1989) Structure-Epileptogenicity Relationship of Quinolones with Special Reference to Their Interaction with Gamma-Aminobutyric Acid Receptor Sites. Antimicrobial Agents and Chemotherapy, 33, 1704-1708. https://doi.org/10.1128/AAC.33.10.1704
|
[55]
|
Tsuji, A., et al. (1988) Inhibitory Effects of Quinolone Antibacterial Agents on Gamma-Aminobutyric Acid Binding to Receptor Sites in Rat Brain Membranes. Antimicrobial Agents and Chemotherapy, 32, 190-194. https://doi.org/10.1128/AAC.32.2.190
|
[56]
|
Williams, P.D. and Helton, D.R. (1991) The Proconvulsive Activity of Quinolone Antibiotics in an Animal Model. Toxicology Letters, 58, 23-28. https://doi.org/10.1016/0378-4274(91)90186-A
|
[57]
|
Smolders, I., Gousseau, C., Marchand, S., Couet, W., Ebinger, G. and Michotte, Y. (2002) Convulsant and Subconvulsant Doses of Norfloxacin in the Presence and Absence of Biphenylacetic Acid Alter Extracellular Hippocampal Glutamate but Not Gamma-Aminobutyric Acid Levels in Conscious Rats. Antimicrobial Agents and Chemotherapy, 46, 471-477. https://doi.org/10.1128/AAC.46.2.471-477.2002
|
[58]
|
Chenel, M., Limosin, A., Marchand, S., Paquereau, J., Mimoz, O. and Couet, W. (2003) Norfloxacin-Induced Electroencephalogram Alteration and Seizures in Rats Are Not Triggered by Enhanced Levels of Intracerebral Glutamate. Antimicrobial Agents and Chemotherapy, 47, 3660-3662. https://doi.org/10.1128/AAC.47.11.3660-3662.2003
|
[59]
|
van der Laan, L.E., et al. (2016) Probable Levofloxacin-Associated Secondary Intracranial Hypertension in a Child with Multidrug-Resistant Tuberculosis. The Pediatric Infectious Disease Journal, 35, 706-708. https://doi.org/10.1097/INF.0000000000001137
|
[60]
|
Thomas, R.J. and Reagan, D.R. (1996) Association of a Tourette-Like Syndrome with Ofloxacin. Annals of Pharmacotherapy, 30, 138-141. https://doi.org/10.1177/106002809603000205
|
[61]
|
O’Brien, J.S. and Sampson, E.L. (1965) Lipid Composition of the Normal Human Brain: Gray Matter, White Matter, and Myelin. Journal of Lipid Research, 6, 537-544. https://doi.org/10.1016/S0022-2275(20)39619-X
|
[62]
|
Hanada, K. (2003) Serine Palmitoyltransferase, a Key Enzyme of Sphingolipid Metabolism. Biochimica et Biophysica Acta, 1632, 16-30. https://doi.org/10.1016/S1388-1981(03)00059-3
|
[63]
|
Donald, P.R. and McIlleron, H. (2009) Chapter 59. Antituberculosis Drugs. In: Schaaf, H.S., et al., Eds., Tuberculosis, W.B. Saunders, Edinburgh, 608-617. https://doi.org/10.1016/B978-1-4160-3988-4.00059-7
|
[64]
|
Chung, S.H., Johnson, M.S. and Gronenborn, A.M. (1984) L-cycloserine: A Potent Anticonvulsant. Epilepsia, 25, 353-362. https://doi.org/10.1111/j.1528-1157.1984.tb04200.x
|
[65]
|
Sundaram, K.S. and Lev, M. (1984) Inhibition of Sphingolipid Synthesis by Cycloserine in Vitro and in Vivo. Journal of Neurochemistry, 42, 577-581. https://doi.org/10.1111/j.1471-4159.1984.tb02716.x
|
[66]
|
Lowther, J., et al. (2010) Inhibition of the PLP-Dependent Enzyme Serine Palmitoyltransferase by Cycloserine: Evidence for a Novel Decarboxylative Mechanism of Inactivation. Molecular BioSystems, 6, 1682-1693. https://doi.org/10.1039/c003743e
|
[67]
|
Laine-Cessac, P., Cailleux, A. and Allain, P. (1997) Mechanisms of the Inhibition of Human Erythrocyte Pyridoxal Kinase by Drugs. Biochemical Pharmacology, 54, 863-870. https://doi.org/10.1016/S0006-2952(97)00252-9
|
[68]
|
Imam, F., et al. (2020) Adverse Drug Reaction Prevalence and Mechanisms of Action of First-Line Anti-Tubercular Drugs. Saudi Pharmaceutical Journal, 28, 316-324. https://doi.org/10.1016/j.jsps.2020.01.011
|
[69]
|
Nair, S., Maguire, W., Baron, H. and Imbruce, R. (1976) The Effect of Cycloserine on Pyridoxine-Dependent Metabolism in Tuberculosis. The Journal of Clinical Pharmacology, 16, 439-443. https://doi.org/10.1002/j.1552-4604.1976.tb02419.x
|
[70]
|
Tang, S., Yao, L., Hao, X., Liu, Y., Sun, H. and Gu, J. (2013) Linezolid for the Treatment of Extensively Drug Resistant Tuberculosis: Multicenter, Randomized Controlled Study. Respirology (Carlton, Vic.), 18, 4.
|
[71]
|
Nam, H.S., Koh, W.J., Kwon, O.J., Cho, S.N. and Shim, T.S. (2009) Daily Half-Dose Linezolid for the Treatment of Intractable Multidrug-Resistant Tuberculosis. The International Journal of Antimicrobial Agents, 33, 92-93. https://doi.org/10.1016/j.ijantimicag.2008.06.014
|
[72]
|
Park, I.N., et al. (2006) Efficacy and Tolerability of Daily-Half Dose Linezolid in Patients with Intractable Multidrug-Resistant Tuberculosis. Journal of Antimicrobial Chemotherapy, 58, 701-704. https://doi.org/10.1093/jac/dkl298
|
[73]
|
Agyeman, A.A. and Ofori-Asenso, R. (2016) Efficacy and Safety Profile of Linezolid in the Treatment of Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Tuberculosis: A Systematic Review and Meta-Analysis. Annals of Clinical Microbiology and Antimicrobials, 15, 41. https://doi.org/10.1186/s12941-016-0156-y
|
[74]
|
von der Lippe, B., Sandven, P. and Brubakk, O. (2006) Efficacy and Safety of Linezolid in Multidrug Resistant Tuberculosis (MDR-TB)—A Report of Ten Cases. Journal of Infection, 52, 92-96. https://doi.org/10.1016/j.jinf.2005.04.007
|
[75]
|
Condos, R., Hadgiangelis, N., Leibert, E., Jacquette, G., Harkin, T. and Rom, W.N. (2008) Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis. Chest, 134, 187-192. https://doi.org/10.1378/chest.07-1988
|
[76]
|
Zhang, P., Li, W., Liu, M., Zhan, S., Zhang, H., Deng, G. and Chen, X. (2022) Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China. Infection and Drug Resistance, 15, 2617-2624. https://doi.org/10.2147/IDR.S365371
|
[77]
|
Singhal, P., Lunia, P., Salgia, K. and Syed, I. (2020) Incidence of Cycloserine Induced Neurotoxicity in Drug Resistant TB Patients Attending a Tertiary Care Hospital. European Respiratory Journal, 56, 1593. https://doi.org/10.1183/13993003.congress-2020.1593
|
[78]
|
Ormerod, L.P. and Horsfield, N. (1996) Frequency and Type of Reactions to Antituberculosis Drugs: Observations in Routine Treatment. Tubercle and Lung Disease, 77, 37-42. https://doi.org/10.1016/S0962-8479(96)90073-8
|
[79]
|
Thee, S., Garcia-Prats, A.J., Donald, P.R., Hesseling, A.C. and Schaaf, H.S. (2016) A Review of the Use of Ethionamide and Prothionamide in Childhood Tuberculosis. Tuberculosis, 97, 126-136. https://doi.org/10.1016/j.tube.2015.09.007
|
[80]
|
Narang, R.K. (1972) Acute Psychotic Reaction Probably Caused by Ethionamide. Tubercle, 53, 137-138. https://doi.org/10.1016/0041-3879(72)90031-1
|
[81]
|
Fortún, J., et al. (2005) Linezolid for the Treatment of Multidrug-Resistant Tuberculosis. Journal of Antimicrobial Chemotherapy, 56, 180-185. https://doi.org/10.1093/jac/dki148
|